About the Company
allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
124
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALLK News
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
Net Loss: Allakos Inc ( NASDAQ:ALLK) reported a net loss of $62.6 million in Q4 2023, widening from $43.0 million in Q4 2022. R&D Expenses: R&D expenses rose to $53.8 million in Q4 2023, up from $35.4 ...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
General and administrative expenses were $11.2 million for the fourth quarter of 2023 compared to $10.8 million for the fourth quarter of 2022, an increase of $0.4 million. The quarter over quarter ...
Hold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developments
LifeSci Capital analyst Sam Slutsky has maintained their neutral stance on ALLK stock, giving a Hold rating today. Sam Slutsky has given his ...
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells ...
Allakos Announces a Restructuring to Focus on Development of AK006
Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to ...
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy ...
Allakos Inc. (ALLK) stock price, news, quote & history – Yahoo Finance
Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells ...
Allakos Inc (37Z.DU)
Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells ...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory ...
Allakos Inc.: Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector ...
Allakos Inc.: Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative ...
Loading the latest forecasts...